Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Implantica AG is a medical technology group dedicated to bringing advanced technology into the body. Its lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux disease (GERD) that has the potential to create a new standard in anti-reflux surgery. Implantica is focused on developing a portfolio of 'smart' implants, utilizing wireless energy transfer and e-health connectivity, to address significant unmet medical needs and enhance patient quality of life through innovative solutions.
The Swiss headquarters serves as the central hub for Implantica's global operations, including strategic leadership, corporate finance, investor relations, and oversight of research, development, and commercialization efforts.
The headquarters likely features modern office facilities conducive to innovation and collaboration, situated within a professional business environment typical of Baar.
Implantica's work culture is expected to be driven by innovation, precision, and a strong ethical commitment to improving patient outcomes, fostering a collaborative environment for its specialized medtech professionals.
Locating the headquarters in Switzerland underscores Implantica's commitment to high-quality standards, precision engineering, and access to a robust European medtech ecosystem and financial markets.
Implantica supports its global aspirations through its headquarters in Switzerland and key operational offices in Liechtenstein and Germany. Its primary functions supported globally include research and development, clinical trial management, manufacturing oversight, regulatory affairs, and the commercialization of its innovative medical implants like RefluxStop™. The company is actively expanding its market presence, particularly in Europe, with a strategy for broader international market entry.
Gewerbestrasse 16
Baar
Zug
Switzerland
Address: Industriering 14, LI-9491 Ruggell
Facilitates Implantica's commercial operations and market access, leveraging Liechtenstein's specific business and regulatory environment for international trade in the medical device sector.
Address: Graf-Adolf-Platz 15, 40213 Düsseldorf
Strengthens Implantica's presence in a key European medtech market, supporting clinical activities, regulatory engagement, and business development within Germany and the EU.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Implantica' leadership includes:
Implantica has been backed by several prominent investors over the years, including:
In the past 12 months, Implantica has seen a key leadership transition in its commercial team with the appointment of a new Head of Sales, Roger Maret, following the departure of the former Chief Commercial Officer. This change aligns with the company's focus on strengthening its sales and market penetration efforts for products like RefluxStop™.
Discover the tools Implantica uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Implantica commonly uses the [first name].[last name]@implantica.com email format for its employees. This is a standard professional email structure, facilitating communication with company representatives.
[first].[last]@implantica.com
Format
peter.forsell@implantica.com
Example
90%
Success rate
Implantica Website / GlobeNewswire • June 4, 2024
Implantica announced that DAK-Gesundheit, one of Germany's largest statutory health insurance companies, has approved reimbursement for its RefluxStop™ device. This significantly expands patient access to the innovative acid reflux treatment in Germany....more
Implantica Website / GlobeNewswire • May 15, 2024
Implantica released its financial results for the first quarter of 2024, highlighting ongoing sales momentum for RefluxStop™, progress in market expansion, and updates on its operational and clinical activities. The report detailed revenue figures and the company's financial position....more
Implantica Website / GlobeNewswire • April 16, 2024
Implantica released its comprehensive Annual Report for the fiscal year 2023. The report summarized the company's financial performance, key strategic achievements including the commercialization of RefluxStop™, research and development milestones, and outlined its strategic outlook for future growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Implantica, are just a search away.